Angiotensin II-mediated MYH9 downregulation causes structural and functional podocyte injury in diabetic kidney disease

Jeong Suk Kang, Seung Joo Lee, Ji Hye Lee, Ji Hee Kim, Seung Seob Son, Seung Kuy Cha, Eun Soo Lee, Choon Hee Chung, Eun Young Lee

Research output: Contribution to journalArticlepeer-review

40 Citations (Scopus)


MYH9, a widely expressed gene encoding nonmuscle myosin heavy chain, is also expressed in podocytes and is associated with glomerular pathophysiology. However, the mechanisms underlying MYH9-related glomerular diseases associated with proteinuria are poorly understood. Therefore, we investigated the role and mechanism of MYH9 in diabetic kidney injury. MYH9 expression was decreased in glomeruli from diabetic patients and animals and in podocytes treated with Ang II in vitro. Ang II treatment and siRNA-mediated MYH9 knockdown in podocytes resulted in actin cytoskeleton reorganization, reduced cell adhesion, actin-associated protein downregulation, and increased albumin permeability. Ang II treatment increased NOX4 expression and ROS generation. The Ang II receptor blocker losartan and the ROS scavenger NAC restored MYH9 expression in Ang II-treated podocytes, attenuated disrupted actin cytoskeleton and decreased albumin permeability. Furthermore, MYH9 overexpression in podocytes restored the effects of Ang II on the actin cytoskeleton and actin-associated proteins. Ang II-mediated TRPC6 activation reduced MYH9 expression. These results suggest that Ang II-mediated MYH9 depletion in diabetic nephropathy may increase filtration barrier permeability by inducing structural and functional podocyte injury through TRPC6-mediated Ca2+ influx by NOX4-mediated ROS generation. These findings reveal a novel MYH9 function in maintaining urinary filtration barrier integrity. MYH9 may be a potential target for treating diabetic nephropathy.

Original languageEnglish
Article number7679
JournalScientific reports
Issue number1
Publication statusPublished - 2019 Dec 1

Bibliographical note

Funding Information:
The authors are grateful to Dr. Lawrence B. Holzman (Renal, Electrolyte and Hypertension Division, University of Pennsylvania School of Medicine, PA, USA) for providing purified anti-MYH9 and anti-MYH10 antibodies. This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2015R1A6A1A03032522, 2017R1D1A3B03027898 and 2018R1A6A3A11040860), the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI17C-2059-010017) and Soonchunhyang University Research Fund.

Publisher Copyright:
© 2019, The Author(s).

All Science Journal Classification (ASJC) codes

  • General


Dive into the research topics of 'Angiotensin II-mediated MYH9 downregulation causes structural and functional podocyte injury in diabetic kidney disease'. Together they form a unique fingerprint.

Cite this